Article and Video CATEGORIES
Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.
Get more information about the FLAURA Trial and TIGER-1 Trial.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi Blaze,
As much as I hate to say it, Welcome back Blaze. It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...
Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3
It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...
Hi and welcome to GRACE. I'm sorry your mom is having this difficulty. An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...